· Published by Health Canada · Official notice
This is duplicated text of a letter from Hospira Healthcare Corporation. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
January 13, 2014
Dear Healthcare Professional,
Subject: Potential for Leakage in Certain Lots of Hospira Flexible Intravenous Containers (1000 mL Intravenous Bags- Sodium Chloride 0.9% Injection USP and Dextrose 5% Injection USP)
Hospira Healthcare Corporation, in consultation with Health Canada, is issuing this Important Safety Information Letter to alert Healthcare Professionals of the potential for leakage in 1000 mL flexible containers (intravenous bags) for certain intravenous solutions. During inspection of a manufactured product lot (which was not released onto the Canadian market), Hospira identified leakage due to a puncture through the overwrap and primary container. The root cause is attributed to a defect in a conveyor belt and corrective actions have since been implemented to prevent reoccurrence. Several product lots are potentially impacted by this issue (refer to the Table below for product lot information).
Leaking intravenous bags may result in compromised sterility and potential for contamination; exposure of the Healthcare Professional or patient to a hazardous drug that has been added to the intravenous solution; a more concentrated solution than intended; or inadequate or inconsistent medication dosing.
| Description | DIN | List Number | Lot No. | Expiry Date |
|---|---|---|---|---|
| Sodium Chloride 0.9% Injection, USP, 1000mL | 00037842 | 07983254 | 32045JT | Aug 1, 2015 |
| Sodium Chloride 0.9% Injection, USP, 1000mL | 00037842 | 07983254 | 34042JT | Oct 1, 2015 |
| Dextrose 5% Injection, USP, 1000mL | 00037915 | 07922254 | 33093JT | Sep 1, 2015 |
Assessing for Leaks:
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious or unexpected adverse reactions in patients receiving intravenous solutions should be reported to Hospira Healthcare Corporation or Health Canada at the following addresses:
Hospira Healthcare Corporation
1111 Dr.-Frederik-Philips, Suite 600
Saint-Laurent (Québec) H4M 2X6
To report an Adverse Reaction, consumers and health professionals may call toll free :
Tel: 1-866-488-6088 Option 6
Fax: 1-877-906-0208
ProductcomplaintsCA@hospira.com
To correct your mailing address or fax number, contact: Hospira Healthcare Corporation.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Health and Product and Food Branch Inspectorate (HPFBI)
E-mail: DCVIU_UVCEM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 1-613-946-5636
Sincerely,
original signed by
Rania Al-Ammar
Regional Director, Commercial Quality
Hospira Healthcare Corporation